NBIX Live signals | Maximize Profits with Getagraph.com

BUY 438 min ago

@ $138.59

Issued: 1 Jul 2024 @ 12:26

Return: 1.10%

Previous signal: Jul 1 - 09:30

Previous signal: Sell

Return: 0.31 %

Live Chart Being Loaded With Signals

Commentary (1 Jul 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 0.00% compare to its pairs and should correct upwards.

Stats
Today's Volume	759 790
Average Volume	797 922
Market Cap	14.10B
EPS	$0.430 ( Q1 \| 2024-05-01 )
Next earnings date	( $1.040 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	38.07 (Sector) 42.63 (Industry) 0
ATR14	$4.04 (2.88%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -2.16%

ALIM -0.72%

AMPH -3.73%

AMYT 0.00%

ANIP -0.38%

AQST -5.77%

ASRT -4.03%

ATNX 0.00%

AVDL 0.43%

AYTU -2.06%

BFRI -0.67%

BGXX 8.76%

CLVR -1.52%

COLL 1.30%

CPIX -3.27%

CRDL -0.99%

CRON -1.29%

CYTH -5.51%

DCPH 0.00%

DERM -4.79%

DRRX 1.55%

DVAX -0.62%

EGRX -1.25%

EMBC -2.80%

EMBCV -9.33%

EOLS 2.12%

ESPR 5.41%

EVOK -10.81%

FLGC -2.94%

FLXN 0.00%

GHSI -2.08%

HCM 2.57%

HROW 0.77%

HUGE -14.49%

IMCC -3.43%

INCR 1.00%

IRWD 0.00%

ITCI -0.73%

IXHL 0.34%

JUPW 11.76%

KALA -2.82%

KIN 0.11%

KMDA -3.40%

LNTH -0.36%

NBIX 1.77%

NEPT 0.00%

NLTX 1.45%

OGI 0.00%

OPTN 0.96%

ORGO -3.57%

PAHC 1.61%

PCRX -0.52%

PETQ 3.67%

PLXP 0.00%

PPD 0.00%

PROC 3.16%

PRPH -2.87%

PTPI -5.66%

RDHL -2.00%

RDUS 0.13%

REPH -0.48%

RGC -5.03%

RMTI -5.11%

SCTL 0.92%

SCYX -2.50%

SIGA -0.53%

SISI -14.23%

SNDL 1.05%

SNOA 8.44%

SSIC -2.37%

SUPN -0.75%

SXTC -2.79%

THTX -1.41%

TKNO -11.68%

TLGT -13.85%

TLRY 1.20%

TXMD 6.21%

TYHT -3.90%

UPC 2.08%

VTRS -0.38%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2024-05-31	Delaet Ingrid	Buy	273	Common Stock
2024-05-31	Delaet Ingrid	Sell	273	Common Stock
2024-05-31	Delaet Ingrid	Sell	273	Non-Qualified Stock Option
2024-05-29	Sherwin Stephen A	Buy	25 000	Common Stock
2024-05-29	Sherwin Stephen A	Buy	15 000	Common Stock

INSIDER POWER
-31.10
Last 100 transactions
Buy: 277 011 \| Sell: 532 232

Correlation (AI algo v.1.1b): Undervalued: 0.00% $140.11 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: 0.46 (neutral)

Short: 0.54 (weak)

Signal:(58) Neutral

Neurocrine Biosciences Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Neurocrine Biosciences Correlation - Currency/Commodity

-0.06
( neutral )

-0.56
( weak negative )

0.00
( neutral )

0.34
( neutral )

0.79
( moderate )

0.38
( neutral )

Neurocrine Biosciences Financials

Annual	2023
Revenue:	$1.89B
Gross Profit:	$1.85B (97.90 %)
EPS:	$2.56

FY	2023
Revenue:	$1.89B
Gross Profit:	$1.85B (97.90 %)
EPS:	$2.56

FY	2022
Revenue:	$1.49B
Gross Profit:	$1.47B (98.44 %)
EPS:	$1.610

FY	2021
Revenue:	$1.13B
Gross Profit:	$1.12B (98.74 %)
EPS:	$0.940

Financial Reports:

No articles found.

Neurocrine Biosciences Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.